New Data on Castle Biosciences’ DecisionDx-SCC and DecisionDx-Melanoma Tests at NCCN 2025 Annual Conference
Castle Biosciences, a leading company in the field of innovative tests for guiding patient care, will present new data on its risk-stratification tests for patients with squamous cell carcinoma (SCC) and cutaneous melanoma (CM) at the NCCN 2025 Annual Conference.
Refining Metastatic Risk Prediction in High-Risk and Very High-Risk SCC Patients
In the first poster presentation, Castle will share data on DecisionDx-SCC in a new, combined validation cohort of 1,412 patients. This study demonstrates that the addition of DecisionDx-SCC to the staging system used at Brigham & Women’s Hospital significantly refines metastatic risk prediction in patients classified as High-Risk and Very High-Risk by the National Comprehensive Cancer Network (NCCN) guidelines.
This improved risk stratification supports more effective, risk-aligned treatment pathway decisions. By identifying patients at higher risk for metastasis, clinicians can take more aggressive measures to prevent or treat metastasis, potentially improving patient outcomes.
DecisionDx-Melanoma: A Significant Predictor of Mortality in Early-Stage CM Patients
In the second poster presentation, Castle will present new data on DecisionDx-Melanoma and its value in identifying patients with early-stage CM who may benefit from treatment plan strategies to improve outcomes.
The new data from a real-world cohort of nearly 7,000 patients shows that DecisionDx-Melanoma is a significant predictor of mortality, reinforcing its value in identifying patients at higher risk for poor outcomes. By providing this information, clinicians can tailor treatment plans to better address the unique needs of individual patients.
Impact on Individuals
For individuals diagnosed with SCC or CM, these new data presentations may lead to more personalized treatment plans based on their specific risk profiles. By using DecisionDx-SCC and DecisionDx-Melanoma tests, clinicians can make more informed decisions about treatment options, potentially improving patient outcomes and quality of life.
Impact on the World
The widespread adoption of these risk-stratification tests could significantly impact the way skin cancer is diagnosed and treated, leading to more effective and personalized care for patients. By providing valuable information about individual patients’ risk profiles, these tests can help clinicians make more informed decisions about treatment options, potentially improving patient outcomes on a global scale.
Conclusion
Castle Biosciences’ DecisionDx-SCC and DecisionDx-Melanoma tests continue to demonstrate their value in the field of skin cancer diagnosis and treatment. The new data presented at the NCCN 2025 Annual Conference further solidifies their role in improving patient outcomes by providing clinicians with valuable information about individual patients’ risk profiles. As these tests become more widely adopted, we can expect to see more personalized and effective treatment plans for patients with SCC and CM.
- DecisionDx-SCC and DecisionDx-Melanoma tests provide valuable information on patients’ risk profiles
- New data presented at NCCN 2025 Annual Conference demonstrates improved risk stratification and mortality prediction
- Adoption of these tests could lead to more personalized and effective treatment plans for patients with SCC and CM
